TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04905316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be performed with external beam ionizing radiation as per standard of care in accordance with institutional practice. Intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist. Patients will be simulated in the treatment position with standard immobilization techniques for thoracic radiotherapy. The prescription dose will be 60 Gy (±10%) in 2Gy fractions to fields encompassing gross tumor and lymph nodes, as per institutional guidelines. The dose must satisfy institutional guidelines and minimize risk to adjacent organs at risk.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
Study: NCT05324631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302, oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302 placebo
Description: SHR0302 placebo, oral, once daily
Study: NCT04518566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudges
Description: Behavioral nudges will be delivered to patients' FitBit device through adaptive intervention platform via notification syncing. To ensure the delivered nudges are timely and personalized, predictive nudges will be developed based on patterns in patients' sociodemographic, clinical and baseline activity tracking. These nudges will be sent automatically to patients upon specific triggers. The nudges will also be assessed for its effectiveness in behavior change. For example, a predictive nudge to encourage patients to take a short walk after detecting long periods of sedentary time will be assessed for its effects by step counts data after delivery of nudge. An iterative approach will be used to generate an effective set of nudges and its most appropriate delivery times for specific activity patterns.
Study: NCT04638309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-548 + Azacitidine
Description: APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
Study: NCT04855435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS8(1V270)
Description: The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
Study: NCT05977296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: To use CPAP
Study: NCT06549335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)
Description: Induction therapy:~The ZGR regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 28 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-28;~2. Obinutuzumab, 1000mg, ivgtt, day 1/8/15 (C1), day1 (C2-6);~3. Lenalidomide, 25 mg qd, po, day 2-11.~Maintenance therapy:~1. Obinutuzumab, ivgtt,1000mg, every 3 months for 2 years;~2. Lenalidomide, 25mg, PO, during 1-10 days in every 28 days for 6 cycles.
Study: NCT05849467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89 Zr-Df-crefmirlimab
Description: an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89 Zr-Df-crefmirlimab
Description: an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours).
Study: NCT06638502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRX215 capsules
Description: HRX215 capsules 250 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRX215 capsules
Description: HRX215 capsules 250 mg orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: placebo capsules matching appearance of HRX215
Study: NCT06564883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.20% sodium hyaluronate gel
Description: Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
Study: NCT06637943

Intervention type: DIAGNOSTIC_TEST
Intervention: POC viscoelastic test
Description: applying viscoelastic test (Rotem or TEG tests) to 1 ml arterial blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: POC viscoelastic test
Description: applying viscoelastic test (Rotem or TEG tests) to 1 ml arterial blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: standard central laboratory test
Description: applying central laboratory test to arterial blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: standard central laboratory test
Description: applying central laboratory test to arterial blood sample
Study: NCT04789941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum + Irinotecan
Description: Studying the efficacy and safety of neoadjuvant cisplatin and irinotecan use in treatment of locally advanced cancer cervix.
Study: NCT05744479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin oral, 2000mg/day, for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo for 24 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Intervention
Description: Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.
Study: NCT05339555

Intervention type: OTHER
Group type: OTHER
Intervention: Instructions for IUD Self-Removal Provided to Participant
Description: The provider will offer any individual presenting for in-person IUD removal or exchange (removal-replacement) the option for self-removal. The participant will be provided a 'how to' instruction sheet with information on positioning and what to expect. The participant will first attempt removal with clean hands if desired, then utilizing non-sterile, clean gloves (not explicitly tested in prior studies) and if that fails, the use of a menstrual cup (a novel technique). If not successful, the provider will perform standard IUD removal in the clinic.
Study: NCT06451146

Intervention type: PROCEDURE
Intervention: PCI Facilitated with Orbital Atherectomy Device
Description: Percutaneous coronary intervention for coronary artery disease supported by the Orbital Atherectomy Device
Study: NCT05643404

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing
Description: Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing
Description: Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.
Study: NCT06532760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling to study sodium fragment kinetics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling to study sodium fragment kinetics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling to study sodium fragment kinetics
Study: NCT06492356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tripolar radiofrequency therapy
Description: Twenty patients underwent weekly TriPollar RF treatment, using a new RF technology with three or more electrodes. Glycerin was applied to the treatment area before and after each session, with the procedure lasting 15 minutes. The technology uses a sequence of electrical modulation to prevent overheating and requires no active cooling of the electrodes or skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medical treatment
Description: Twenty patients will receive medical treatment by dermatologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment
Description: Twenty patients will receive medical treatment by dermatologist.
Study: NCT05564325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deflectable guidewire
Description: A deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care guidewire (different models may be used)
Description: The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
Study: NCT06328946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment
Description: including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study: NCT06185400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Description: RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Description: RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: RC48+pyrotinib after EGFR-TKIs progression
Study: NCT05368285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration
Study: NCT05453864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CMAP Plus TFCBT
Description: This will include 8 individual sessions of CMAP Plus TFCBT delivered by a trained therapist over a period of 12 weeks. Each session will last between 45 to 60 minutes.
Study: NCT05506709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seawater nasal spray
Description: Subjects will use the nasal spray (moderately hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and calcium) at least once and up to 6 times as necessary per day during the 14-day test period. Each application is composed of two irrigating sprays per nostril for a total of 4 sprays per application.
Study: NCT06157853

Intervention type: OTHER
Group type: OTHER
Intervention: Sunscreen
Description: Bland sunscreen to be used by subjects after cleansing and the facial moisturizer during the 7-day washout period. Bland sunscreen to be used by subjects after cleansing and after the active post-procedure cream and comparator anhydrous cream. Use the provided sunscreen and reapply as needed throughout the day and per recommendation of the FDA, every 2 hours.
Study: NCT06080373

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROBECO
Description: Spanish participants in the active control group will undergo the PROBECO program, designed by the Spanish Penitentiary Agency for various violent crimes. It aims to eradicate criminal behavior, reduce recidivism, and teach social skills. It has four phases.~German participants will be placed in social therapeutic facilities for compulsory psychotherapy focused on relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Formulation-based cognitive behavioral therapy
Description: The CBT program includes these core modules:~A. ADHD Psychoeducation: Provides information on ADHD characteristics, neurobiology, treatments, and their efficacy. Shared with a significant other if available.~B. Planning Skills and Distraction Management: Teaches time management, task prioritization, and distraction control techniques.~C. Cognitive Restructuring: Based on Ellis' Rational Behavioral Emotive Therapy, it helps participants identify and modify irrational thoughts for better emotional regulation.~D. Maintenance of Treatment Gains: Reviews progress, identifies risk factors, and develops action plans for post-treatment challenges.
Study: NCT06027112

Intervention type: OTHER
Intervention: musculoskeletal injuries
Description: This research will be conducted to identify the factors that increase the risk of musculoskeletal injuries in university students,

Intervention type: OTHER
Intervention: musculoskeletal injuries
Description: This research will be conducted to identify the factors that increase the risk of musculoskeletal injuries in university students,
Study: NCT05542953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]APN-1607
Description: In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
Study: NCT05368285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration
Study: NCT05542953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]APN-1607
Description: In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]APN-1607
Description: In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
Study: NCT05368285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Subcutaneous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Subcutaneous Administration
Study: NCT05779514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Health Volunteers ：Mirabegron p.o. 28 days 100mg qd./ Tumor patients ：Mirabegron p.o. 28 days 100 mg qd or 200 mg qd.
Study: NCT04124263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational short message texts
Description: Educational messages for patient engagement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational short message texts
Description: Educational messages for patient engagement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence short message texts
Description: Reminder messages of medication use time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence short message texts
Description: Reminder messages of medication use time
Study: NCT05301400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bti Unit
Description: Comparison with or without the device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bti Unit
Description: Comparison with or without the device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bti Unit
Description: Comparison with or without the device
Study: NCT05585567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-01/V-01-B5
Description: Contains 10μg of V-01 and 10μg of V-01-B5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-01-351/V-01-B5
Description: Contains 10μg of V-01-351 and 10μg of V-01-B5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-01
Description: Contains 10μg of V-01